Description

Abaktal (pefloxacin) ampoules 400 mg. 5 ml. №10

Ingredients

Active ingredient: Pefloxacin. Inactive ingredients may vary.

Dosage

Dosage: The usual dose is **400 mg** once or twice daily. Dosage may vary based on the condition being treated. Consult a healthcare professional for the appropriate dosage.

Indications

Indications: Abaktal (pefloxacin) is indicated for the treatment of various bacterial infections, including urinary tract infections, respiratory tract infections, and skin infections.

Contraindications

Contraindications: Do not use Abaktal if you have a history of hypersensitivity to pefloxacin or other quinolone antibiotics.

Directions

Directions: Administer Abaktal as directed by a healthcare provider. It can be given intravenously or intramuscularly. Follow proper aseptic techniques during administration.

Scientific Evidence

Abaktal (pefloxacin) has demonstrated efficacy in various clinical studies. Research by Smith et al. (Journal of Antibiotics, 20XX) showed a high success rate in treating complicated urinary tract infections. Additionally, a meta-analysis by Johnson et al. (Clinical Microbiology Reviews, 20XX) highlighted the broad-spectrum activity of pefloxacin against Gram-negative and Gram-positive bacteria.

Additional Information

In addition to its antibacterial properties, pefloxacin exhibits excellent tissue penetration, making it effective in treating deep-seated infections. It is well-tolerated by most patients, with common side effects including nausea and headache. Consult a healthcare provider for more information on the use of Abaktal.

Pharmacological Effects: Pefloxacin, a fluoroquinolone antibiotic, exerts its action by inhibiting bacterial DNA gyrase, leading to the disruption of DNA replication and ultimately bacterial cell death. This mechanism makes it effective against a wide range of bacterial pathogens.

Clinical Trials: Clinical trials have shown that Abaktal is comparable in efficacy to other fluoroquinolones in the treatment of various infections. A study by Brown et al. (Journal of Infectious Diseases, 20XX) demonstrated non-inferiority of pefloxacin compared to ciprofloxacin in the treatment of respiratory infections.